University hospital
Montpellier, 34295, France
NCT Number: NCT07160465
It is an interventional research, single-blind, randomized, controlled, multicenter, which involves only minimal risks and constraints.
Patients who attend to the emergency department following a SA (Suicidal Attempt) represent a key group of patients with an extremely high risk of suicide in the short term.
A main problem in suicide prevention is that the increase of symptoms and suicidal risk occurs most often in the natural environment of patients, away from the system of care. Thus, the main goal in allowing real-time risk detection would facilitate immediate interventions, probably the best way to prevent a suicidal act. Additionally, the evolution of the suicidal crisis is very variable from one subject to another, in duration and symptoms, and often very brief. In contrast, the tools used to assess suicidal thoughts have so far been limited to intermittent assessments separated by weeks, months or years, which does not take into account the fact that suicidal thoughts can be highly variable over a few hours and that suicide attempts can occur in response to a rapid increase in thoughts over periods as short as the day. Mobile health (mHealth) interventions are the only that can respond to these fluctuations over time.
We have developed the first French app (emma) for EMA (Ecological Momentary Assessment) , customised EMI (Ecological Momentary Intervention) and prediction of SB (suicidal behaviour). It was designed by integrating evidence-based suicide prevention strategies and recommendations for the development of apps in the field of mental health. Emma helps to strengthen the patient's connection to his healthcare system and social network. This study led to the development and subsequent deployment of VigilanS. VigilanS is a multi-regional innovative care program for the prevention of suicide relapse, which has been implemented in several emergencies departments in France.
Our hypothesis is that emma offers an unprecedented opportunity to increase the efficiency of VigilanS, both for patients, by restoring their social connections, and for health professionals, in a simple, fast and efficient way. Thanks to emma, the patient will have daily support adapted to his condition (emotion management modules, safety plan, calls in case of emergency). Emma will fit easily into the daily practice of health professionals (little binding, little time consuming) and will complete the range of care organized by VigilanS.
The main objective is to evaluate over a 6-months follow-up the efficacy of a smartphone app (emma) in addition to the VigilanS program on the prevention of a suicidal event (suicide, SA, hospitalization or emergency department for suicidal ideation) compared to the VigilanS program only.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Montpellier, 34295, France
632 participants will be enrolled and randomized into 2 groups:
The duration of inclusions is 24 months. Each patient's participation period is 6 months and includes three visits (inclusion, at 3 and 6 months).
At each visit, a clinical assessment will be performed to characterise psychopathology and suicidal characteristics.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: within 6 months of inclusion.
The primary endpoint is the occurrence of a suicidal event (suicide, SA, hospitalization, or emergency admission for suicidal ideation) within 6 months of inclusion.
Time frame: Up to 6 months after study inclusion
Intensity and severity of suicidal ideation assessed with C-SSRS.
Time frame: Up to 6 months after study inclusion
Level of psychological pain assessed by a validated Likert scale.
Time frame: Up to 6 months after study inclusion
Level of depression assessed by QIDS
Time frame: Up to 6 months after study inclusion
Level of loneliness assessed by ESUL
Time frame: Up to 6 months after study inclusion
Level of social isolation assessed by ISI
Time frame: Up to 6 months after study inclusion
Level of hopelessness assessed by BHS
Time frame: number of care visit until the end of the study, an average of 6 months
Number of care visits for psychiatric problems and/or suicidal ideation
Time frame: Semi-directive interviews during the visit at 6 months
Semi-directive interviews conducted with patients who agree to participate in the qualitative study, to explore experiences related to psychiatric care and suicidal ideation.
Time frame: Up to 6 months after study inclusion
Frequency of connection.
Time frame: within 6 months of inclusion.
Acceptability and satisfaction of patients assessed by monthly questionnaires in the app (Likert scales), by a self-questionnaire to be completed at the last visit (MARS scale) and, for 30 patients who agree to participate in the qualitative study, during the qualitative evaluation of the experience of emma users.
Contact information is provided by the study sponsor or research team.
Emilie OLIE, MD PhD
CONTACT
Philippe COURTET, MD PhD
CONTACT
University Hospital, Montpellier
Other
Efficacy of a Smartphone Suicide Prevention App: A Single-blind, Randomized, Controlled Multicenter Study
Acronym: PreventS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07284238
Behavior, Behavioral Symptoms
Barcelona, Spain
View Trial DetailsNCT06353711
Behavior, Behavioral Symptoms
Charlotte, North Carolina, United States
View Trial DetailsNCT07404787
Behavior, Behavioral Symptoms
Bethesda, Maryland, United States
View Trial DetailsNCT07383714
Behavior, Behavioral Symptoms
Dallas, Texas, United States
View Trial Details